|
|
||||||||
The Annals of Thoracic Surgery, Vol 54, 1031-1036, Copyright © 1992 by The Society of Thoracic Surgeons
DM Cosgrove 3d, B Heric, BW Lytle, PC Taylor, R Novoa, LA Golding, RW Stewart, PM McCarthy and FD Loop
We tested the efficacy and safety of aprotinin in 169 patients undergoing
isolated reoperative myocardial revascularization. Patients were randomly
assigned to high-dose aprotinin, low-dose aprotinin, or placebo treatment
groups in a double-blind, placebo-controlled study. Treatment groups did
not differ significantly with respect to age, sex, red cell mass, number of
grafts, use of internal thoracic artery, or incidence of preoperative
aspirin therapy. Patients treated with aprotinin had a significant
reduction in postoperative chest tube drainage (720 +/- 753, 866 +/- 1,636,
and 1,121 +/- 683 mL, respectively, for high-dose aprotinin, low-dose
aprotinin, and placebo; p < 0.001). Transfusion requirements were
reduced in aprotinin-treated patients (2.1 +/- 4.2, 4.8 +/- 11.8, and 4.1
+/- 6.2 units for high- dose, low-dose, and placebo, respectively; p <
0.001). A similar reduction in chest tube drainage and transfusion
requirements was seen in patients using aspirin preoperatively. Q-wave
myocardial infarctions were increased in the aprotinin subgroups (17.5%,
14.3%, and 8.9% for high-dose, low-dose, and placebo groups; not
significant). Acute vein graft thrombosis was found in six of 12 vein
grafts studied at postmortem examination in patients receiving aprotinin
but not in any of five grafts in patients receiving placebo. We conclude
that aprotinin is extremely effective in reducing bleeding and transfusion
requirements and may increase the risk of graft thrombosis.
ARTICLES
Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study
Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic Foundation, Ohio 44195.
This article has been cited by other articles:
![]() |
D. L. Ngaage, A. R. Cale, M. E. Cowen, S. Griffin, and L. Guvendik Aprotinin in primary cardiac surgery: operative outcome of propensity score-matched study. Ann. Thorac. Surg., October 1, 2008; 86(4): 1195 - 1202. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Olenchock Jr, P. H.U. Lee, T. Yehoshua, S. A. Murphy, J. Symes, and G. Tolis Jr Impact of aprotinin on adverse clinical outcomes and mortality up to 12 years in a registry of 3,337 patients. Ann. Thorac. Surg., August 1, 2008; 86(2): 560 - 566. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. M. Sundt The demise of aprotinin: Our share of the blame. J. Thorac. Cardiovasc. Surg., April 1, 2008; 135(4): 729 - 731. [Full Text] [PDF] |
||||
![]() |
S. Westaby Aprotinin: Twenty-five years of claim and counterclaim J. Thorac. Cardiovasc. Surg., March 1, 2008; 135(3): 487 - 491. [Full Text] [PDF] |
||||
![]() |
A. DeAnda Jr. Aprotinin and Cardiac Surgery J. Thorac. Cardiovasc. Surg., March 1, 2008; 135(3): 492 - 494. [Full Text] [PDF] |
||||
![]() |
C. L. Backer, A. M. Kelle, R. D. Stewart, S. C. Suresh, F. N. Ali, R. A. Cohn, R. Seshadri, and C. Mavroudis Aprotinin is safe in pediatric patients undergoing cardiac surgery. J. Thorac. Cardiovasc. Surg., December 1, 2007; 134(6): 1421 - 1428. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. J. Van der Linden, J.-F. Hardy, A. Daper, A. Trenchant, and S. G. De Hert Cardiac surgery with cardiopulmonary bypass: does aprotinin affect outcome? Br. J. Anaesth., November 1, 2007; 99(5): 646 - 652. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Mehr-Aein, M. Sadeghi, and M. Madani-civi Does Tranexamic Acid Reduce Blood Loss in Off-Pump Coronary Artery Bypass? Asian Cardiovasc Thorac Ann, August 1, 2007; 15(4): 285 - 289. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Brown, N. J.O. Birkmeyer, and G. T. O'Connor Meta-Analysis Comparing the Effectiveness and Adverse Outcomes of Antifibrinolytic Agents in Cardiac Surgery Circulation, June 5, 2007; 115(22): 2801 - 2813. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. M. Mannucci and M. Levi Prevention and Treatment of Major Blood Loss N. Engl. J. Med., May 31, 2007; 356(22): 2301 - 2311. [Full Text] [PDF] |
||||
![]() |
C. W. Hogue and M. J. London Aprotinin's Effect on ACT is Not an Artifact Anesth. Analg., May 1, 2007; 104(5): 1302 - 1303. [Full Text] [PDF] |
||||
![]() |
The Society of Thoracic Surgeons Blood Conservatio, V. A. Ferraris, S. P. Ferraris, S. P. Saha, E. A. Hessel II, C. K. Haan, B. D. Royston, C. R. Bridges, R. S.D. Higgins, G. Despotis, et al. Perioperative Blood Transfusion and Blood Conservation in Cardiac Surgery: The Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists Clinical Practice Guideline Ann. Thorac. Surg., May 1, 2007; 83(5_Supplement): S27 - S86. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. T. Mangano, Y. Miao, A. Vuylsteke, I. C. Tudor, R. Juneja, D. Filipescu, A. Hoeft, M. L. Fontes, Z. Hillel, E. Ott, et al. Mortality Associated With Aprotinin During 5 Years Following Coronary Artery Bypass Graft Surgery JAMA, February 7, 2007; 297(5): 471 - 479. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. B. Ferguson Jr Aprotinin--Are There Lessons Learned? JAMA, February 7, 2007; 297(5): 527 - 529. [Full Text] [PDF] |
||||
![]() |
A. Mehr-Aein, S. Davoodi, and M. Madani-Civi Effects of Tranexamic Acid and Autotransfusion in Coronary Artery Bypass Asian Cardiovasc Thorac Ann, February 1, 2007; 15(1): 49 - 53. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. C. Harle and J. M. Murkin Another bleeding heart: perioperative heparin management revisited/Un autre coeur qui saigne : une reevaluation de l'anticoagulation a l'heparine Can J Anesth, February 1, 2007; 54(2): 97 - 102. [Full Text] [PDF] |
||||
![]() |
A. Ronald and J. Dunning Does use of aprotinin decrease the incidence of stroke and neurological complications in adult patients undergoing cardiac surgery? Interactive CardioVascular and Thoracic Surgery, December 1, 2006; 5(6): 767 - 773. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C. Body and C. D. Mazer Pro: Aprotinin Has a Good Efficacy and Safety Profile Relative to Other Alternatives for Prevention of Bleeding in Cardiac Surgery Anesth. Analg., December 1, 2006; 103(6): 1354 - 1359. [Full Text] [PDF] |
||||
![]() |
C. W. Hogue and M. J. London Aprotinin Use During Cardiac Surgery: A New or Continuing Controversy? Anesth. Analg., November 1, 2006; 103(5): 1067 - 1070. [Full Text] [PDF] |
||||
![]() |
A. Vincentelli, B. Jude, and S. Belisle Antithrombotic therapy in cardiac surgery: [Traitement antithrombotique en chirurgie cardiaque]. Can J Anesth, June 1, 2006; 53(6_suppl): S89 - S102. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. T. Mangano, I. C. Tudor, C. Dietzel, and the Multicenter Study of Perioperative Ischemia Re The Risk Associated with Aprotinin in Cardiac Surgery N. Engl. J. Med., January 26, 2006; 354(4): 353 - 365. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. J. Vlahakes The Value of Phase 4 Clinical Testing N. Engl. J. Med., January 26, 2006; 354(4): 413 - 415. [Full Text] [PDF] |
||||
![]() |
R. S. Poston, C. White, J. Gu, J. Brown, J. Gammie, R. N. Pierson, A. Lee, I. Connerney, T. Avari, R. Christenson, et al. Aprotinin Shows Both Hemostatic and Antithrombotic Effects During Off-Pump Coronary Artery Bypass Grafting Ann. Thorac. Surg., January 1, 2006; 81(1): 104 - 111. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. Fischer and M. Steinhoff Effects of aprotinin on endothelium-dependent relaxation of large coronary arteries Eur. J. Cardiothorac. Surg., December 1, 2005; 28(6): 801 - 804. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Vanek, M. Jares, R. Fajt, Z. Straka, K. Jirasek, M. Kolesar, P. Brucek, and M. Maly Fibrinolytic inhibitors in off-pump coronary surgery: a prospective, randomized, double-blind TAP study (tranexamic acid, aprotinin, placebo) Eur. J. Cardiothorac. Surg., October 1, 2005; 28(4): 563 - 568. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. H. Kincaid, D. A. Ashburn, J. R. Hoyle, M. G. Reichert, J. W. Hammon, and N. D. Kon Does the Combination of Aprotinin and Angiotensin-Converting Enzyme Inhibitor Cause Renal Failure After Cardiac Surgery? Ann. Thorac. Surg., October 1, 2005; 80(4): 1388 - 1393. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Sedrakyan Improving clinical outcomes in coronary artery bypass graft surgery Am. J. Health Syst. Pharm., September 15, 2005; 62(18_Supplement_4): S19 - S23. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Kher, K. K. Meldrum, K. L. Hile, M. Wang, B. M. Tsai, M. W. Turrentine, J. W. Brown, and D. R. Meldrum Aprotinin improves kidney function and decreases tubular cell apoptosis and proapoptotic signaling after renal ischemia-reperfusion J. Thorac. Cardiovasc. Surg., September 1, 2005; 130(3): 662 - 662. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Fergusson, K. C. Glass, B. Hutton, and S. Shapiro Randomized controlled trials of aprotinin in cardiac surgery: could clinical equipoise have stopped the bleeding? Clinical Trials, June 1, 2005; 2(3): 218 - 232. [Abstract] [PDF] |
||||
![]() |
A. Sedrakyan, T. Treasure, and J. A. Elefteriades Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: A systematic review and meta-analysis of randomized clinical trials J. Thorac. Cardiovasc. Surg., September 1, 2004; 128(3): 442 - 448. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. K. Smith, S. K. Datta, L. H. Muhlbaier, G. Samsa, A. Nadel, and J. Lipscomb Cost analysis of aprotinin for coronary artery bypass patients: analysis of the randomized trials Ann. Thorac. Surg., February 1, 2004; 77(2): 635 - 642. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. P. Taggart, V. Djapardy, M. Naik, and A. Davies A randomized trial of aprotinin (Trasylol) on blood loss, blood product requirement, and myocardial injury in total arterial grafting J. Thorac. Cardiovasc. Surg., October 1, 2003; 126(4): 1087 - 1094. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Karski and J. T. Balatbat Blood Conservation Strategies in Cardiac Surgery Seminars in Cardiothoracic and Vascular Anesthesia, June 1, 2003; 7(2): 175 - 188. [Abstract] [PDF] |
||||
![]() |
R. Salenger, J. S. Gammie, and T. J. Vander Salm Postoperative Care of Cardiac Surgical Patients Card. Surg. Adult, January 1, 2003; 2(2003): 439 - 469. [Full Text] |
||||
![]() |
D. T. Mangano and the Multicenter Study of Perioperative Ischemia Re Aspirin and Mortality from Coronary Bypass Surgery N. Engl. J. Med., October 24, 2002; 347(17): 1309 - 1317. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Tweddell, G. M. Hoffman, K. A. Mussatto, R. T. Fedderly, S. Berger, R. D. B. Jaquiss, N. S. Ghanayem, S. J. Frisbee, and S. B. Litwin Improved Survival of Patients Undergoing Palliation of Hypoplastic Left Heart Syndrome: Lessons Learned From 115 Consecutive Patients Circulation, September 24, 2002; 106(12_suppl_1): I-82 - I-89. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ulker, P. P McKeown, and U. Bayraktutan Aprotinin impairs coronary endothelial function and down-regulates endothelial NOS in rat coronary microvascular endothelial cells Cardiovasc Res, September 1, 2002; 55(4): 830 - 837. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Samama, O. Langeron, N. Rosencher, X. Capdevila, P. Rouche, M. Pegoix, J. Berniere, and P. Coriat Aprotinin Versus Placebo in Major Orthopedic Surgery: A Randomized, Double-Blinded, Dose-Ranging Study Anesth. Analg., August 1, 2002; 95(2): 287 - 293. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Murkin, J. Maurer, and S. Niemcryk Full dose aprotinin administration is associated with a significant decrease in perioperative stroke in patients undergoing elective cardiac surgery: a meta-analysis Ann. Thorac. Surg., January 1, 2002; 73(1): S374 - 374. [Full Text] [PDF] |
||||
![]() |
M D Linden, M Schneider, and W N Erber Factor VLEIDEN and cardiopulmonary bypass: investigation of haemostatic parameters and the effect of aprotinin using an ex vivo model Perfusion, December 1, 2001; 16(6): 476 - 484. [Abstract] [PDF] |
||||
![]() |
S. Beholz, J. Liu, R. Thoelke, C Spiess, and W. Konertz Use of desmopressin and erythropoietin in an anaemic Jehovah's Witness patient with severely impaired coagulation capacity undergoing stentless aortic valve replacement Perfusion, December 1, 2001; 16(6): 485 - 489. [Abstract] [PDF] |
||||
![]() |
R. C. Landis, G. Asimakopoulos, M. Poullis, D. O. Haskard, and K. M. Taylor The antithrombotic and antiinflammatory mechanisms of action of aprotinin Ann. Thorac. Surg., December 1, 2001; 72(6): 2169 - 2175. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. C. Landis, D. O. Haskard, and K. M. Taylor New antiinflammatory and platelet-preserving effects of aprotinin Ann. Thorac. Surg., November 1, 2001; 72(5): S1808 - 1813. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. J. Despotis, M. S. Avidan, and C. W. Hogue Jr Mechanisms and attenuation of hemostatic activation during extracorporeal circulation Ann. Thorac. Surg., November 1, 2001; 72(5): S1821 - 1831. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Murkin Attenuation of neurologic injury during cardiac surgery Ann. Thorac. Surg., November 1, 2001; 72(5): S1838 - 1844. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. T. Mora Mangano, M. J. Neville, P. H. Hsu, I. Mignea, J. King, and D. C. Miller Aprotinin, Blood Loss, and Renal Dysfunction in Deep Hypothermic Circulatory Arrest Circulation, September 18, 2001; 104(90001): I-276 - 281. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kottke-Marchant and S. Sapatnekar Hemostatic Abnormalities in Cardiopulmonary Bypass: Pathophysiologic and Transfusion Considerations Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2001; 5(3): 187 - 206. [Abstract] [PDF] |
||||
![]() |
S. Ulker, M. G. Cinar, U. Bayraktutan, and A. Evinc Aprotinin impairs endothelium-dependent relaxation in rat aorta and inhibits nitric oxide release from rat coronary endothelial cells Cardiovasc Res, June 1, 2001; 50(3): 589 - 596. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Ruel, F. Wang, M. E. Bourke, J.-Y. Dupuis, J. A. Robblee, W. J. Keon, and F. D. Rubens Is tranexamic acid safe in patients undergoing coronary endarterectomy? Ann. Thorac. Surg., May 1, 2001; 71(5): 1508 - 1511. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Gott Leukodepletion and aprotinin improve clinical outcome after extracorporeal circulation Perfusion, January 1, 2001; 16(1_suppl): 5 - 9. [Abstract] [PDF] |
||||
![]() |
M. De Bonis, F. Cavaliere, F. Alessandrini, E. Lapenna, F. Santarelli, U. Moscato, R. Schiavello, and G. F. Possati TOPICAL USE OF TRANEXAMIC ACID IN CORONARY ARTERY BYPASS OPERATIONS: A DOUBLE-BLIND, PROSPECTIVE, RANDOMIZED, PLACEBO-CONTROLLED STUDY J. Thorac. Cardiovasc. Surg., March 1, 2000; 119(3): 575 - 580. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. V Moran, G. Lema, J. Medel, M. J Irarrazaval, R. Zalaquett, B. Garayar, and R. Flaskamp Comparison of two doses of aprotinin in patients receiving aspirin before coronary bypass surgery Perfusion, March 1, 2000; 15(2): 105 - 110. [Abstract] [PDF] |
||||
![]() |
F. Forestier, S. Belisle, D. Robitaille, R. Martineau, L. P. Perrault, and J.-F. Hardy Low-dose aprotinin is ineffective to treat excessive bleeding after cardiopulmonary bypass Ann. Thorac. Surg., February 1, 2000; 69(2): 452 - 456. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. P. Bidstrup, B. J. Hunt, S. Sheikh, R. N. Parratt, J. M. Bidstrup, and R. N. Sapsford Amelioration of the bleeding tendency of preoperative aspirin after aortocoronary bypass grafting Ann. Thorac. Surg., February 1, 2000; 69(2): 541 - 547. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Klein, P.R. Keith, H.-P. Dauben, H.D. Schulte, H. Beckmann, G. Mayer, O. Elert, and E. Gams Aprotinin counterbalances an increased risk of peri-operative haemorrhage in CABG patients pre-treated with Aspirin Eur. J. Cardiothorac. Surg., October 1, 1999; 14(4): 360 - 366. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Lentschener, P. Cottin, H. Bouaziz, F. J. Mercier, M. Wolf, Y. Aljabi, C. Boyer-Neumann, and D. Benhamou Reduction of Blood Loss and Transfusion Requirement by Aprotinin in Posterior Lumbar Spine Fusion Anesth. Analg., September 1, 1999; 89(3): 590 - 590. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M.H. Khan, N. Gikakis, S. Miyamoto, A. K. Rao, S. L. Cooper, L. H. Edmunds Jr, and R. W. Colman Aprotinin inhibits thrombin formation and monocyte tissue factor in simulated cardiopulmonary bypass Ann. Thorac. Surg., August 1, 1999; 68(2): 473 - 478. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. R. Smith and T. B. Spanier Aprotinin in deep hypothermic circulatory arrest Ann. Thorac. Surg., July 1, 1999; 68(1): 278 - 286. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Miyashita, Y. Hayashi, Y. Ohnishi, and M. Kuro Retrospective analysis of effect of low-dose aprotinin priming on allogeneic blood transfusion in repeated cardiac operations Perfusion, May 1, 1999; 14(3): 189 - 194. [Abstract] [PDF] |
||||
![]() |
J. J. Munoz, N. J. O. Birkmeyer, J. D. Birkmeyer, G. T. O'Connor, and L. J. Dacey Is {epsilon}-Aminocaproic Acid as Effective as Aprotinin in Reducing Bleeding With Cardiac Surgery? : A Meta-Analysis Circulation, January 12, 1999; 99(1): 81 - 89. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Hyde, J. A Chinn, and T. R Graham Platelets and cardiopulmonary bypass Perfusion, December 1, 1998; 13(6): 389 - 407. [PDF] |
||||